Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Overview of attention for article published in Clinical Cancer Research, November 2005

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

twitter: 3 X users
patent: 7 patents

wikipedia: 3 Wikipedia pages

Readers on

mendeley: 73 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,623 followers.

RT @Kennydoesbio: Will $VINC fix MEDI-522 (αvβ3 mAB) fail (0% ORR, n=25), by adding camptothecin payload? What are examples of mAB fails,…

Will $VINC fix MEDI-522 (αvβ3 mAB) fail (0% ORR, n=25), by adding camptothecin payload? What are examples of mAB fails, where ADC improved? https://t.co/ddW0qRCVXs

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.